Ruxolitinib S enantiomer

• CAT Number: I005595
• CAS Number: 941685-37-6
• Molecular Formula: C17H18N6
• Molecular Weight: 306.37
• Purity: ≥95%
• Synonyms: S-Ruxolitinib
• Target: Stem Cell/Wnt
• Solubility: in DMSO > 10 mM
• Storage: 3 years -20C powder
• IC50: 3.3 nM/2.8 nM(JAK1/JAK2)
• IUPAC Name: (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
• InChI: 1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m0/s1
• InChIKey: HFNKQEVNSGCOJV-HNNXBMFYSA-N
• SMILES: C1CCC(C1)[C@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Ruxolitinib S enantiomer (Cat No.: I005595) is the stereoisomer of ruxolitinib, a potent and selective Janus kinase (JAK) inhibitor primarily targeting JAK1 and JAK2. The S enantiomer retains significant activity in modulating cytokine signaling pathways involved in myeloproliferative disorders, inflammation, and autoimmune diseases. It contributes to the overall pharmacological profile of racemic ruxolitinib, which is approved for treating conditions like myelofibrosis and polycythemia vera. Studying the S enantiomer helps clarify stereospecific effects, optimize drug design, and enhance the therapeutic targeting of JAK-related pathways.

Reference

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.


[2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807.